clinical trial · NCT06772168
Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
CMG Pharmaceutical Co. Ltd·phase3·recruiting·n = 240
DyslipidemiaType 2 DiabetesCMG190303(Dapagliflozin/Rosuvastatin)Comparator 1: Dapagliflozin/Rosuvastatin placeboRosuvastatin/Dapagliflozin placebo
brief summary
The goal of this clinical trial is to learn if drug CMG190303 to treat Type 2 Diabetes and Dyslipidemia in adults. It will also learn about the safety of CMG190303. The main questions it aims to answer are: -Primary Objectives: 1. To compare the change in HbA1c from baseline to 24 weeks between CMG190303 and Rosuvastatin 2. To compare the change in LDL-C from baseline to 24 weeks between CMG190303 and Dapagliflozin
started
Apr 19, 2024
primary completion
Nov 4, 2026
completion
Feb 1, 2027
last updated
Jan 15, 2026
official title
A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol